Infliximab Dose Reduction Sustains the Clinical Treatment Effect in Active HLAB27 Positive Ankylosing Spondylitis: A Two-Year Pilot Study

The rationale of the study was to evaluate the efficacy of infliximab (IFX) treatment in patients with ankylosing spondylitis (AS) and to determine whether IFX dose reduction and interval extension sustains the treatment effect. Nineteen patients were included and treated with IFX 5 mg/kg every 6 we...

Descripción completa

Detalles Bibliográficos
Autores principales: Mörck, Boel, Pullerits, Rille, Geijer, Mats, Bremell, Tomas, Forsblad-d'Elia, Helena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3780705/
https://www.ncbi.nlm.nih.gov/pubmed/24089587
http://dx.doi.org/10.1155/2013/289845

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3780705/
https://www.ncbi.nlm.nih.gov/pubmed/24089587
http://dx.doi.org/10.1155/2013/289845

Ejemplares similares